Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3346893 | 1.00 | UCHL1 (0.42) | UCHL1ABCB1ACHEMCL1GRM2 | |
| SCHEMBL3346899 | 1.00 | UCHL1 (0.42) | UCHL1ABCB1ACHEMCL1GRM2 | |
| SCHEMBL12891831 | 0.84 | POLB (0.43) | UCHL1ABCB1MCL1PARP1 | |
| SCHEMBL7287734 | 0.84 | ABCB1 (0.52) | UCHL1ABCB1MCL1AGTR2 | |
| SCHEMBL3179881 | 0.84 | ABCB1 (0.52) | UCHL1ABCB1MCL1AGTR2 | |
| SCHEMBL26604823 | 0.84 | ABCB1 (0.52) | UCHL1ABCB1MCL1AGTR2 | |
| SCHEMBL376159 | 0.84 | ABCB1 (0.52) | UCHL1ABCB1MCL1AGTR2 | |
| SCHEMBL1448119 | 0.84 | ABCB1 (0.52) | UCHL1ABCB1MCL1AGTR2 | |
| SCHEMBL949983 | 0.84 | ABCB1 (0.52) | UCHL1ABCB1MCL1AGTR2 | |
| SCHEMBL708630 | 0.84 | ABCB1 (0.52) | UCHL1ABCB1MCL1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41894-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-RE41356-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-05-25 | — | — | US | disclosed |
| EP-1105413-B1 | HEPATITIS C INHIBITOR TRI-PEPTIDES | BOEHRINGER INGELHEIM CA LTD (CA) | 2009-04-29 | — | — | EP | disclosed |
| EP-2028186-A2 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-02-25 | — | — | EP | disclosed |
| US-RE40525-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| EP-1105422-B1 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-02-15 | — | — | EP | disclosed |
| EP-1003775-B1 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM CA LTD (CA) | 2005-03-16 | — | — | EP | disclosed |
| EP-1012180-B1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGUES | BOEHRINGER INGELHEIM CA LTD (CA) | 2004-12-01 | — | — | EP | disclosed |
| US-6767991-B1 | PEPTIDES AND ANALOGS THEREOF; VIRAL PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH PEPTIDES AND RIBAVIRIN | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-07-27 | — | — | US | disclosed |
| US-6420380-B2 | FOR TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-07-16 | — | — | US | disclosed |
| US-6410531-B1 | FOR THERAPY OF HEPATITIS C VIRUS (HCV) INFECTION | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-06-25 | — | — | US | disclosed |
| US-20020037998-A1 | Hepatitis C inhibitor tri-peptides | LLINAS-BRUNET MONTSE (CA) | 2002-03-28 | — | — | US | disclosed |
| US-20020016442-A1 | Hepatitis C inhibitor tri-peptides | LLINAS-BRUNET MONTSE (CA) | 2002-02-07 | — | — | US | disclosed |
| US-6329379-B1 | OLIGOPEPTIDES FOR INHIBITING HEPATITIS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6329417-B1 | RACEMATES, DIASTEREOISOMERS AND OPTICAL ISOMERS; PROTEASE INHIBITOR PEPTIDE ANALOG | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6323180-B1 | PROTEASE INHIBITORS; INHIBIT REPLICATION OF HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2001-11-27 | — | — | US | disclosed |
| US-6268207-B1 | RESOLUTION OF ENANTIOMERS FROM A MIXTURE OF (1R,2S)/(1S,2S)-1-AMINO-2-VINYLCYCLOPROPYL CARBOXYLIC ACID METHYL ESTER COMPRISING THE STEP OF TREATING SAID MIXTURE WITH AN ESTERASE TO OBTAIN THE CORRESPONDING (1R,2S) ENANTIOMER | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-07-31 | — | — | US | disclosed |
| US-6143715-A | FOR TREATING AND PREVENTION OF HEPATITIS C VIURS INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037998-A1 | Hepatitis C inhibitor tri-peptides | LIPC, HAVCR2, HCCS | UCHL1 3305/4885ABCB1 2958/4885ACHE 4859/4885 |
| US-20020016442-A1 | Hepatitis C inhibitor tri-peptides | HAVCR2, LIPC, HCCS | UCHL1 3390/4885ABCB1 2885/4885ACHE 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.